Stereoselective Steady‐State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults
- 9 May 2020
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 108 (5), 1036-1048
- https://doi.org/10.1002/cpt.1888
Abstract
The antidepressant bupropion is stereoselectively metabolized and metabolite enantiomers have differential pharmacologic effects, but steady-state enantiomeric disposition is unknown. Controversy persists about bupropion XL 300 mg generic equivalence to brand product, and whether generics might have different stereoselective disposition leading to enantiomeric non-bioequivalence and, thus, clinical nonequivalence. This preplanned follow-on analysis of a prospective, randomized, double-blinded, crossover study of brand and 3 generic bupropion XL 300 mg products measured steady-state enantiomeric plasma and urine parent bupropion and primary and secondary metabolite concentrations and evaluated bioequivalence and pharmacokinetics. Steady-state plasma and urine bupropion disposition was markedly stereoselective, with up to 40-fold differences in plasma concentrations of the active metabolite S,S-hydroxybupropion vs. R,R,-hydroxybupropion. Urine metabolite glucuronides were prominent, but glucuronidation was metabolite-specific and enantioselective. There were no differences between any generic and brand, or between generics, in plasma enantiomer concentrations of bupropion or the major metabolites. All generic products satisfied formal bioequivalence criteria (peak plasma concentration (Cmax) and area under the plasma concentration-time curve over 24 hours (AUC0–24)) using enantiomers for bupropion as well as for metabolites, and generics were comparable to each other, and were considered bioequivalent, based on enantiomeric analysis. Enantiomeric bioequivalence explains the previously observed therapeutic equivalence of bupropion generics and brand in treating major depression. These results have important implications for understanding the clinical therapeutic effects of bupropion based on complex and stereoselective metabolism.Keywords
This publication has 40 references indexed in Scilit:
- Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady statePharmacogenetics and Genomics, 2013
- Metrics for the Evaluation of Bioequivalence of Modified-Release FormulationsThe AAPS Journal, 2012
- Effects of Hydroxymetabolites of Bupropion on Nicotine Dependence Behavior in MiceThe Journal of pharmacology and experimental therapeutics, 2010
- Synthesis and Characterization of in Vitro and in Vivo Profiles of Hydroxybupropion Analogues: Aids to Smoking CessationJournal of Medicinal Chemistry, 2010
- Rapid Clinical Induction of Hepatic Cytochrome P4502B6 Activity by RitonavirAntimicrobial Agents and Chemotherapy, 2008
- Stereoselective Bupropion Hydroxylation as an In Vivo Phenotypic Probe for Cytochrome P4502B6 (CYP2B6) ActivityThe Journal of Clinical Pharmacology, 2008
- Stereoselective Metabolism of Bupropion by Cytochrome P4502B6 (CYP2B6) and Human Liver MicrosomesPharmaceutical Research, 2008
- Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MSJournal of Chromatography B, 2007
- Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic ReceptorsMolecular Pharmacology, 2004
- Pharmacokinetic Optimisation of Sustained-Release Bupropion for Smoking CessationDrugs, 2002